Patent applications publishing

Makriyannis and Liu claimed a series of pyrazole analogues in a patent application published in 2003 [272]. Of the 29 compounds specifically exemplified in the patent application, compound (389) was demonstrated to reduce lever presses when administered to rats that were trained to expect delivery of a food pellet as the outcome. It was proposed that the reduction in lever pressing was the result of decreased appetite brought about by CBi receptor antagonism. 

JAPIO. This database is produced by the Japan Patent Information Organization and is based on the Patent Abstracts of Japan provided by the Japanese Patent Office. The database is updated monthly and contains all Kokai Tokyo Koho (published unexamined patent applications) published as of October 1976. Records appear in JAPIO approximately six months after publication of the unexamined patent application. English language abstracts are provided for the majority of applications filed by Japanese applicants. Applications by non-Japanese applications do not have abstracts, but bibliographic information is included. Searchable fields include the International Patent Office Classification and JAPIO classification (96). 

A published U.S. patent application can be readily distinguished from an issued U.S. patent by the publication code at the top right-hand side of the application. In contrast to an issued U.S. patent, which is indicated by a single unique patent number (e.g., 7,415,989), a published patent application will first list the year followed by a slash and a seven digit code. For example, a U.S. patent application published in 2009 might have a publication number of US2009/0123456. 

Since January 1, 1956, printed copies of West German patent applications published for opposition have become available, involving less delay and eyestrain than the photostatic copies of typed pages obtained previously. 

Japan Patent Office. URL http //www.jpo.go.jp/. Information in English and Japanese about Japanese patent, design, and trademark law and searchable databases in Japanese and English. The Patent and Utility Model Gazette, Patent Abstracts of Japan, and Trademark databases are in English. Status information and document copies are displayable and machine translations can be generated for Japanese patent applications published since 1993. 

WIPO— WO patent applications published in last 24 months. 

According to a patent application published in 1996 [24] (Scheme 21.2) fosetyl-aluminium can be prepared by combining phosphorus trichloride with a stoichiometric amount of ethanol (85-100%) at temperatures below 20 °C followed by... 

MH Hanna, P York. Method and apparatus for the formation of particles. Patent application, published as WO 95/01221, 1995. 

SM Cooper. A novel polymorphic crystalline form of fluticasone propionate. A method for its production and pharmaceutical compositions thereof. Patent application, published as WO 98/17676, 1997. 

In the patent literature, Aventis has published a patent application covering hydroxamic acid containing macrocycles (39) with the same general template as the A-formyl-A-hydroxylamine macrocycles described above [114] and GlaxoSmithKline has published an application on macrocyclic PDF inhibitors containing a hydrazide scaffold (40) [115], No data has been published on these inhibitors to date. 

A patent application from Merck Frosst, published in 1997, discloses CB2 selective compounds with modified core structures where the pyran oxygen is replaced by nitrogen, such as (342), which has a K of around 64 nM at CB2 and around 25,000 nM at CBi [217]. 

Several groups have published on structural analogues of (382), one of the earliest being the disclosure of CP 272871 (383) from Pfizer, which displays lower affinity for the CBi receptor than (382), in addition to reduced selectivity over the CB2 receptor subtype. Both (382) and (383) have been shown to act as inverse agonists rather than neutral antagonists in vitro [265]. A recently published patent application from Sanofi-Aventis claims a series of 4-cyanopyrazole analogues of (382), with 42 specific examples [266]. 

Motors support for a long-range scientific study of the poisonous gasoline additive, tetraethyl lead. Besides trouble-shooting for various Du Pont departments, Carothers published 60 papers and was listed as the inventor or coinventor of 69 U.S. patent applications during his nine years at Du Pont. Research and development were so new to American corporations that Carothers assistants drafted and he edited patent applications for Du Pont lawyers. You were supposed to be so on top of the literature that you knew whether this was something new or not.. . . Those patents are really classical scientific papers, Hill explained. Carothers considered himself unfit to be a clerk or inventor, but he dominated Du Pont s patent application process for almost a decade. 

Existing synthetic methods and commercial processes that employ nitrile hydratases (NHases) and nitrilases continue to be improved by directed evolution of existing enzymes, or by the discovery of new enzymes with improved properties, and new applications of these catalysts have recently been described. Numerous reviews have previously been published that describe applications of NHase [ 1-6] and nitrilase [ 1,4—11 ], and in this review we present examples of new applications of these nitrile-utilizing catalysts from journal articles, patent applications, and issued patents that have been published in the past 2-3 years. 

There are no published reports in the scientific literature on the extraction and purification of PHA from transgenic plant material on the medium- to large-scale necessary for commercial production of PHA in agricultural crops. There are, however, a number of issued patents and patent applications which describe... 

Several patent applications claiming a class of inhibitors derived from the DA transporter (DAT) inhibitor methylphenidate (12) have been published [48-50], A variety of structural modifications represented by analogs 13-15 have been claimed and pharmacological data has been reported for analog SSR-504734 (13) [51-53]. 

Other patent applications for scaffolds derived from methylphenidate have been published (16-18) however, no pharmacological data has been reported [57-59]. 

Several patent applications claiming variations represented by scaffold 42 have been published [81]. A developed PET ligand from this scaffold class, [11C]-GSK931145 (43) [82], was used in a Phase I study designed to evaluate the relationship between plasma concentrations and brain occupancy of GSK1018921 in healthy individuals (structure and data not disclosed) [46],... 

Quinoline-derived GlyT-1 inhibitors, represented by analog 48, have also been claimed in published patent applications [90]. Functional IC50 data has been provided for several examples, with values ranging between 10 and 1000 nM. 

Two recently published patent applications [44,45] extended previously described work by the same group [21]. Enzymatic data in the patent applications is reported in ranges (<1, 1-10, >10 iM, etc), making it difficult to thoroughly assess the compounds covered in the claims. Bissulfonamide 35 is a representative compound and is reported to inhibit both ACC1 and ACC2 with IC50 s < 5 iM. 

Sharpless, B.K., Fokin, V., Rostovtsev, V.V., Green, L., and Himo, F. (2005) Copper-catalysed ligation of azides and acetylenes. US Patent Application 2005/0222427 Al, published October 6, 2005, filed May 30, 2003 provisional application filed May 30, 2002. 

---